ConnectiveRx

Overview

ConnectiveRx is the largest independent (non-pharmacy-affiliated) provider of outsourced patient access and commercialization services to pharmaceutical manufacturers. The company serves 120+ pharma customers across 530+ brands, with relationships with all top-20 pharma companies. Headquartered in Whippany, NJ, ConnectiveRx generated $413M in LTM revenue (August 2022) with $132M in EBITDA (32% margin) and has grown at a 13% CAGR since 2019.

The company was acquired by Kohlberg & Company in late 2022 from HP SCF (Stone Canyon Industries), which had held the asset since 2019. Prior to that, ConnectiveRx was backed by Bain Capital. The current management team — CEO Jim Corrigan, COO Bob Shambaugh, and CDO Jim Mahon — were recruited from ERT (a $600M+ revenue clinical trial technology company) in 2021 to drive the next phase of growth.

ConnectiveRx’s core strategic position is as the only independent provider with top-tier capabilities across all three major commercialization service lines: Hub Solutions, Copay, and Awareness & Adherence. This cross-segment positioning enables bundled sales and integrated data visibility that point-solution competitors cannot match.

Services & Capabilities

Hub Solutions (46% of revenue, ~$182M LTM)

Tech-enabled call center and web portal managing the reimbursement process for specialty drugs:

• Hub Services: Benefits verification and prior authorization for self-administered specialty drugs
• Buy & Bill: Reimbursement management for physician-administered drugs (injectables)
• Cash Claims: Subsidizes 100% of drug cost before insurance coverage (first 12-18 months post-launch); proprietary technology using existing copay infrastructure
• Revenue model: 41% monthly management fees (recurring), 53% transaction fees (re-occurring tied to script volume), 6% service fees (one-time)
• CRx sweet spot: small/mid-tier hubs requiring 10-75 FTEs at ~$55k/head, $2-8M annual contract value
• FTE composition: ~60% call center, ~20% data management, ~5% program management
• 50% gross margin, 24% contribution margin, 18% FCF margin
• 20% CAGR (2019-2022); fastest-growing segment driven by specialty drug volume and share gains
• 38 brand wins in 2021, 31 in YTD Q3-2022; 104-119% net retention

Copay (27% of revenue, ~$116M LTM)

Pharma-sponsored copay card design, management, and distribution:

• Integrated with pharmacy systems to subsidize patient out-of-pocket costs at point of dispensing
• Revenue model: 25% monthly management fees, 69% transaction fees (~$2.50 per redemption), 6% service fees
• Cash claims sub-segment (29% of Copay revenue): percentage-based on total drug cost
• 71% gross margin, 57% contribution margin, 55% FCF margin
• Highly automated; minimal FTE burden
• Top-3 copay provider in the market
• ~96% gross retention (losses driven by LOE — copay not applicable to generics)
• 5% CAGR since 2015; 3% CAGR 2019-LTM (COVID-impacted)

Awareness & Adherence (28% of revenue, ~$111M LTM)

EHR-integrated messaging to prescribers, pharmacists, and patients:

• Network of EHR integrations reaching ~70% of U.S. HCPs
• Messages delivered at time of prescribing (ScriptGuide), during EHR workflow (Physician Care), or at pharmacy fill (CarePoint)
• Revenue model: 98% transaction fees (~$2.00/message), 2% service fees; 3-month contract buy-ups
• Top-2 market position
• ~100% net retention despite shorter-term contracts
• 47% gross margin, 38% contribution margin, 37% FCF margin
• ~50% of revenue is revenue share with EHR partners
• Post-COVID expansion added 150k providers (~30% network increase)

Competitive Position

ConnectiveRx is the leading independent provider in a $3.0-3.5 billion served market growing 7-9% annually (2022-2027E). The company competes against both large integrated players and smaller point-solution providers.

Key competitive advantages:

• Only independent provider with top-tier capabilities across Hub, Copay, and A&A — enabling bundled sales
• 40-50% win rate across all services they compete for
• 98% customer retention driven by high switching costs (mission-critical, deeply integrated with drug launch operations)
• Strong clinical pipeline alignment — current business mix overlaps with Phase III assets in Oncology, CNS, Autoimmune, and Metabolic/Endocrinology
• 68% of revenue is recurring/re-occurring (management fees + script-volume-tied transaction fees)

Key limitations:

• No owned specialty pharmacy (limits addressable market for mega-hub programs requiring in-house dispensing)
• Hub margins (50% gross) are lower than Copay (71%) and A&A (47%) due to FTE-intensive operations
• A&A segment (28% of revenue) relies on 3-month contract buy-ups (non-recurring)
• Services not applicable to generic drugs; revenue tied to branded/specialty drug lifecycles

Comparable transaction context: Pharma services companies have traded at 19-25x EBITDA in recent PE transactions (mean 19.2x, median 18.8x), reflecting the mission-critical, recurring-revenue nature of these businesses.

Recent Developments

• Late 2022: Acquired by Kohlberg & Company from HP SCF / Stone Canyon. Kohlberg plans to leverage advisory members and portfolio company Trinity Life Sciences to improve go-to-market strategy.
• 2021-2022: New C-suite installed from ERT (CEO Jim Corrigan, COO Bob Shambaugh, CDO Jim Mahon)
• 2022: Hub margin improvement program underway — targeting 3.1% gross margin expansion through OCR automation ($3.4M annualized savings), tools consolidation ($1.4M), resource pooling ($1.5M), eBV ($0.4M), and call software ($1.3M)
• 2022: Enterprise Data Warehouse initiative underway ($2.9M capex in 2022, $4.0M in 2023) to enable cross-segment data visibility and bundled service analytics
• Priority M&A: Specialty pharmacy acquisition identified as top strategic priority to expand Hub addressable market; oncology-focused hub add-ons also being evaluated

Client & Partner Ecosystem

• Relationships with all top-20 pharma companies
• 120+ pharma customers, 530+ brands
• Top customers: Novo Nordisk (13% of revenue — Ozempic, Rybelsus), Amgen (12%), AbbVie (8%), UCB (7%), Genentech (5%)
• Top brands: Ubrelvy (5%), Cimzia (5%), Xarelto (5%), Ozempic (4%), Rybelsus (4%)
• EHR network partnerships covering ~70% of U.S. HCPs (A&A segment)
• Revenue split: 65% specialty drugs, 35% traditional drugs (77%/23% excluding A&A)

Technology Platform

• Hub portal: Web-based patient enrollment and benefits verification data entry platform
• Call center technology: Multi-program call center with cross-trained FTEs; investing in call monitoring and bot call software
• OCR (Optical Character Recognition): Software to read and input Buy & Bill data, replacing manual FTE processes
• Electronic Benefit Verification (eBV): Electronic BV replacing phone-based FTE verification
• Hub CRM: New CRM platform under development ($5.2M capex in 2022) to consolidate case management tools
• Hub Data Re-Platform: Major data infrastructure modernization ($5.8M in 2022) to improve reporting and program management
• Enterprise Data Warehouse: Cross-segment data integration initiative ($2.9M in 2022, $4.0M in 2023) to enable bundled service analytics
• EHR integration network: Covers ~70% of U.S. HCPs for A&A messaging (ScriptGuide, Physician Care, CarePoint products)

Therapeutic Focus

Broad coverage across specialty therapeutic areas with strongest positioning in:

• Autoimmune / Immunology (Cimzia/UCB, AbbVie products)
• Metabolic & Endocrinology (Ozempic, Rybelsus / Novo Nordisk)
• Neurology (Ubrelvy)
• Cardiovascular (Xarelto)
• Oncology (growing focus, primary M&A target for TA expansion)
• CNS

Target Customers

Pharmaceutical and biotechnology manufacturers, particularly:

• Large pharma companies with broad brand portfolios (enterprise-level relationships, ~4 brands per customer)
• Emerging biotech with specialty drug launches requiring hub support
• Sweet spot: sponsors of drugs with >$10k annual cost, reimbursement hurdles, and 10k+ patient populations

Recent Developments (2024-2026)

Note: The following developments come from Perplexity Wave 2 research (April 2026) and update the IC memo-sourced profile above with public information through Q1 2026.

Ownership Update — Genstar Sale Process Active. The IC memos reference a Kohlberg & Company acquisition in late 2022. As of the Perplexity research cutoff (April 2026), publicly available sources tell a different story: Genstar Capital’s own portfolio page lists ConnectiveRx as a current investment, and Octus (formerly Reorg) reported in November 2025 that Genstar is actively exploring a sale through William Blair, with second-round bidding underway. No public announcement confirming Kohlberg’s acquisition has been located in available public sources — suggesting either the transaction occurred under different terms than the IC memos anticipated, or the Kohlberg reference in the IC memos reflected a deal that was not consummated as described. This discrepancy warrants clarification through direct diligence. For the purposes of this profile, the IC memo financial data (which was sourced from internal PE materials) is preserved alongside the publicly-sourced ownership narrative.

Leadership Changes. Harry Totonis (co-founder, former CEO of Surescripts) returned as Chairman and CEO in January 2023 after Jim Corrigan stepped down. Current C-suite: Brett Weinblatt (CFO, ex-AST Financial Group), Gwyn Plaskon (COO, ex-Medable), Cindy Baksh (CPO, ex-Cencora), Snehal Desai (CTO, ex-Cardinal Health — notable hire, previously oversaw 400-person AI/ML team), Laura Blair (CCO, ex-Roche/AbbVie), Jim Caponi (GC/CCO, ex-Walgreens).

Scale Update (2025-2026). ConnectiveRx now claims to support 90M+ patients annually (vs. IC memo ~30M implied touch points), engage 1.6M HCPs, manage 550+ brand programs across 140+ pharma manufacturer clients, and process ~$6.5B in patient benefits per year. Headcount estimated at ~1,700-1,800 employees (vs. ~1,300 at IC memo time). Revenue estimated at ~$280-300M per ZoomInfo (vs. $413M LTM per IC memo — discrepancy likely reflects different measurement methodologies or scope).

July 2024 — RxLink Partnership. Integrated RxLink’s MedMap platform (reaching 20M+ patients through health system networks) into ConnectiveRx’s affordability platform for real-time, text-delivered prescription savings at point of care.

September 2025 — ConnectiveRx Pharmacy Launch. The most significant product development since the IC memos: ConnectiveRx launched a fully licensed dispensing pharmacy enabling end-to-end direct-to-patient (DTP) distribution. This directly addresses the #1 strategic gap identified in the Kohlberg value creation plan — the lack of owned pharmacy capability that limited ConnectiveRx’s addressable market for mega-hub programs. CEO Totonis: “This strategic move allows ConnectiveRx to manage the complete patient journey from intake through fulfillment.”

November 2025 — Sale Process Reported. Octus reports Genstar exploring full exit via William Blair with strong buyer interest and second-round bidding active. Genstar’s hold has extended to ~10 years (initial investment 2015, recap 2020), well beyond typical PE timelines.

December 2025 — Conference Leadership. ConnectiveRx executives took leading roles at both the Copay, Reimbursement and Access Congress and Patient Support Services Congress, presenting on AI in hub services, accumulator/maximizer strategies, and the evolving access landscape.

March 2026 — 1.2M Provider Network Milestone. ConnectiveRx publicly emphasized its clinically integrated provider engagement network covering 1.2M prescribers inside clinical workflows (up from ~70% of U.S. HCPs cited in IC memos). Highlights 13-15% higher first-fill rates in recent brand programs across cardiovascular, diabetes, and women’s health.

Snehal Desai CTO Hire (2024). A notable signal: Desai previously served as Chief Data and Analytics Officer at Cardinal Health, overseeing a 400-person AI/ML organization. Appointment signals serious intent to develop AI capabilities within the hub platform.

EHR Network Expansion. Exclusive partnerships with Veradigm and Athena Health remain in place. ConnectiveRx’s EHR messaging network generates physician-level prescribing data (PLD) for pharma manufacturer analytics — a significant data asset that competitors lack at comparable scale.

Z CEO transition (Jan 2023)](https://njbiz.com/connectiverx-ceo-steps-down-founder-returns/), RxLink Partnership (July 2024), Pharmacy Launch (Sep 2025), Octus Sale Report (Nov 2025), 1.2M Provider Network (Mar 2026)